Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 4
1967 1
1970 1
1971 1
1972 1
1973 2
1976 1
1978 2
1979 2
1980 2
1981 1
1982 2
1983 2
1984 2
1985 2
1986 9
1987 27
1988 72
1989 116
1990 100
1991 112
1992 122
1993 129
1994 110
1995 203
1996 226
1997 289
1998 380
1999 424
2000 341
2001 396
2002 370
2003 349
2004 325
2005 295
2006 333
2007 369
2008 404
2009 304
2010 362
2011 421
2012 494
2013 589
2014 627
2015 640
2016 663
2017 653
2018 605
2019 282
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

10,372 results
Results by year
Filters applied: . Clear all
Page 1
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Filippatos TD, et al. Curr Opin Lipidol 2018 - Review. PMID 29994840
Thus, a role of PCSK9 in the development of atherosclerosis, in vascular wall inflammation and in platelet function has been suggested. ...Additionally, a controversial role of PCSK9 in sepsis, hepatitis C infection and Alzheimer's disease has been suggested. SUMMARY: These possible pleiotropic effects of PCSK9 inhibitors need further research, as they may affect cardiovascular risk and provide further insights in the development of atherosclerosis and other diseases such as Alzheimer's disease or chronic viral infection and sepsis....
Thus, a role of PCSK9 in the development of atherosclerosis, in vascular wall inflammation and in platelet funct …
Adverse effects of the angiotensin-converting enzyme inhibitors.
Alderman CP. Ann Pharmacother 1996 - Review. PMID 8773167
DATA SOURCES: Online drug information sources, including MEDLINE (1966-November 1994), Iowa Drug Information Service, and the Australian Medical Index (AMI), were used to identify relevant literature, including reviews. ...CONCLUSIONS: Attention to the principles of risk assessment, risk immunization, and patient monitoring are important when ACE inhibitor therapy is used for any indication. ...
DATA SOURCES: Online drug information sources, including MEDLINE (1966-November 1994), Iowa Drug Information Ser …
Drug interactions with new oral anticoagulants in elderly patients.
Stöllberger C. Expert Rev Clin Pharmacol 2017 - Review. PMID 28825849
This review attempts to summarise what is known about Drug-drug interactions (DDIs) of the new oral anticoagulants (NOACs) in elderly patients. ...DDIs were reported most frequently in association with dabigatran. Dabigatran is the only NOAC interacting with proton-pump-inhibitors. ...
This review attempts to summarise what is known about Drug-drug interactions (DDIs) of the new oral anticoagulants (NOACs) …
Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants
Eikelboom JW, et al. Br J Anaesth 2018 - Review. PMID 29576106 Free article.
Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. ...Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required....
Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxa …
Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril.
Materson BJ. Am J Cardiol 1992 - Review. PMID 1546639
Quinapril is a new ACE inhibitor that is converted to biologically active quinaprilat in the liver. This ACE inhibitor has a rapid onset of action and inhibits local tissue converting enzyme systems in kidney, heart, and brain, as well as in the circulating renin-angiotensin system. ...In other studies, headache was reported by up to 4.7% of patients receiving quinapril, which is comparable to reported incidences of headache in patients receiving other ACE inhibitors. ...
Quinapril is a new ACE inhibitor that is converted to biologically active quinaprilat in the liver. This ACE …
Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence.
Gavazzoni M, et al. Eur J Pharmacol 2018 - Review. PMID 29550338
Recent pre-clinical studies have investigated the effects of proteasome on myocardial and vascular cells, but the pathogenic mechanism underlying the effects of proteasome inhibition on these cells is poorly understood. We reviewed the evidence from clinical trials, post-hoc analysis and small observational studies currently available and summarized the data from experimental, focusing on the pathogenic mechanisms potentially implicated in the cardiovascular toxicity of proteasome inhibitor, particularly of carfilzomib that is most responsible for cardiovascular side effects. ...
Recent pre-clinical studies have investigated the effects of proteasome on myocardial and vascular cells, but the pathogenic mechanis …
Anticoagulants and Breastfeeding
Anderson PO. Breastfeed Med 2017 - Review. PMID 28051322
Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.
Parish RC and Miller LJ. Drug Saf 1992 - Review. PMID 1536695
When dietary potassium intake is regulated and sources of altered potassium excretion are identified, hyperkalaemia is seldom a serious problem. ...An unexpected finding emerging in recent years is the dry cough associated with ACE inhibitor therapy. Its mechanism is not definitely known. ...
When dietary potassium intake is regulated and sources of altered potassium excretion are identified, hyperkalaemia …
Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction : meta-analysis of randomised clinical trials.
Agustí A, et al. Drug Saf 2003. PMID 12959631
There is ample evidence that ACE inhibitors improve the symptoms and prognosis of chronic heart failure (CHF) and ventricular dysfunction. However, there is little systematic information on the tolerability and adverse effects associated with their use in these conditions. ...
There is ample evidence that ACE inhibitors improve the symptoms and prognosis of chronic heart failure (CHF) and ventr …
Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis.
Overbeek JA, et al. Diabetes Metab Res Rev 2018 - Review. PMID 29573125
The long-term impact of dipeptidyl peptidase-4 (DPP-4) inhibition is unknown, and there are concerns about the influence of DPP-4 inhibition on carcinogenesis of the pancreas and thyroid. ...Based on the current literature, it is not possible to conclude whether DPP-4 inhibitors were associated with an increased risk of site-specific cancer. ...
The long-term impact of dipeptidyl peptidase-4 (DPP-4) inhibition is unknown, and there are concerns about the influ
10,372 results
Jump to page
Feedback